ShangPharma Touts Growth in its Biologics Division

ShangPharma, the Shanghai CRO, announced its biologics division is performing ahead of schedule on two projects, and the company expects to sign several contracts for new biologics projects soon that will add more business. ShangPharma says the biologics division will have close to 100 employees on board by the end of 2011. More details.... Stock Symbol: (NYSE: SHP)     Share this with colleagues: